Friday 6 November 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue: +2,356.5%
EPS: +46.3%
Free cash flow: −6.73%
Total debt: −83.9%

Quarter to September 2026, against a year earlier

54.67 0.88 −1.58%

Follow CYTK

Alert me

Market cap: $7.7B
P/E: 0.0×
Fwd P/E: −10.3×
Dividend yield: —
F-score: 2/9
Altman Z: −1.98
Beneish M: −0.44
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Cytokinetics, Incorporated (CYTK) P/E ratio

Alert me on P/E ratio

Cytokinetics, Incorporated has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 243× (April 2017) — the current reading is the lowest in ten years.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/CYTK/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Cytokinetics, Incorporated P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/CYTK/metrics/pe-ratio">Cytokinetics, Incorporated (CYTK) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	0.0×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	32.6×	—

Period	P/E ratio	Change
Sep 2026	0.0×	—
Jun 2026	0.0×	—
Mar 2026	0.0×	—
Dec 2025	0.0×	—
43 more quarters	Free account

Against its own ten years

Low 0.0× High 243×

Ten-year median 0.0×

Current reading's percentile 96

Company	P/E ratio
TWST Twist Bioscience Corporation compare	n/m
SYRE Spyre Therapeutics, Inc. compare	n/m
CYTK Cytokinetics, Incorporated	n/m
MDGL Madrigal Pharmaceuticals, Inc. compare	n/m
ARWR Arrowhead Pharmaceuticals, Inc. compare	n/m
KRYS Krystal Biotech, Inc. compare	39.2×
CORT Corcept Therapeutics Incorporated compare	47.5×
CAI Caris Life Sciences,�Inc. compare	77.7×
PTGX Protagonist Therapeutics, Inc. compare	111×
Biotechnology industry median	10.3×
Healthcare sector median	25.2×
Market median	17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Cytokinetics, Incorporated (CYTK) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on CYTK

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on CYTK

Stockrow Weekly